

U.S. Patent Appl. No. 09/840,872  
Attorney Docket No. 037003-0280609

**RECEIVED**  
**CENTRAL FAX CENTER**

**APR 13 2005**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re PATENT APPLICATION OF

Antonio J. GRILLO-LOPEZ et al.

Group Art Unit: 1642

Application Serial No. 09/840,872

Examiner: Gary B. Nickol

Filed: April 25, 2001

Title: INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR TREATMENT OF  
CENTRAL NERVOUS SYSTEM LYMPHOMAS

\* \* \* \* \*

**AMENDMENT PURSUANT TO 37 C.F.R. 1.114**

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is in response to the official action [final rejection] dated July 26, 2004, wherein the claims were rejected under 35 U.S.C. § 102(b) and § 103(a) and under the judicially created doctrine of obviousness-type double patenting. The instant amendment is submitted with a request for continued examination pursuant to 37 C.F.R. 1.114 along with payment of the requisite fee.